We have devised a strategy based on polymerase chain reaction (PCR) for the rapid cloning offunctional antibody genes as single-chain immunotoxins. RNA from a hybridoma producing an antibody (OVB3) that reacts with ovarian cancer cells was used as a template to make the first strand of a cDNA. Then a second strand was synthesized and amplified by using two sets of DNA primers that (t) hybridized to the ends of the light-and heavy-chain variable regions, (iU) encoded a linker peptide, and (uit) contained appropriate restriction enzyme sites for cloning. After 30 cycles of PCR, the DNA fragments containing sequences encoding the light-and heavy-chain variable regions were cloned into an Escherichia coi expression vector containing a portion of the Pseudomonas exotoxin gene. Clones encoding recombinant single-chain immunotoxins were expressed in E. coli and the protein product was assessed for its ability to bind to or kill cells bearing the OVB3 antigen. By using this approach it should be possible to rapidly clone the functional variable region sequences of many different antibodies from hybridoma RNA.
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"Targeted toxins" represent a different approach to cytocidal therapy (1, 2) . For this purpose, protein toxins have been chemically attached to monoclonal antibodies (mAbs) to make immunotoxins (1, 2), or genes encoding toxins have been fused to growth factor genes to create growth factor-toxin fusion proteins (3) . Recently, fragments of antibodies containing the antigen binding site(s) have been produced in Escherichia coli either as two chains or as single-chain antibodies (4) (5) (6) (7) . We have produced a recombinant single-chain immunotoxin, antiTac (Fv)-PE40, which consists of the variable domains of a mAb directed at the interleukin 2 receptor linked to a modified 40 kDa form of Pseudomonas exotoxin (PE40) (8) . To construct single-chain immunotoxins, only the DNA sequences encoding the variable domains of the light and heavy chains of an antibody and that of a toxin are required.
Polymerase chain reaction (PCR) is now widely used for genomic and cDNA cloning (9) (10) (11) . Recently, PCR has been used to amplify genes encoding variable domains of antibodies (12) (13) (14) . Here we describe a PCR-based method ofcloning the variable light-and heavy-chain (VL and VH) genes of an antibody directly from total RNA. The genes are expressed in E. coli fused to PE as a functional single-chain immunotoxin. We have now used this method to clone the VL and VH of mAb OVB3, an antibody that reacts with many human ovarian cancers (15 Table 1 ). Two sets of two primers each were devised for the amplification of the VL and VH of murine mAb OVB3 (see Fig. 1A ). VL-5' was based on the N-terminal amino acid sequence of the OVB3 light chain and contained 23 nucleotides encoding the N-terminal amino acids of the light chain and an Nde I site 5' to these nucleotides. VL-3' contained a Sal I site, nucleotides complementary to those encoding a linker peptide, and its 3' end was complimentary to the joining (J) region of a mouse K light chain. VH-5' contained a Sal I site and 20 nucleotides encoding the N-terminal amino acids of the heavy chain.
VH-3' contained a HindIII site and its 3' end was complementary to the J region of the heavy chain.
RNA Isolation, cDNA Synthesis, and Amplification. RNA was prepared from =5 x 107 hybridoma cells (17) . Total RNA was used for first strand cDNA synthesis using random primers at 370C for 1 hr in a 200-,l reaction mixture containing 40 ,ug of total RNA, 6.6 ,l of RNase-and DNase-free bovine serum albumin (3 (21) . N-terminal amino acid sequencing of light and heavy chains of OVB3 was performed after their separation on SDS/polyacrylamide gel and transblotting onto Immobilon membranes (Millipore).
RESULTS

Identification of Rare Restriction Enzyme Sites and Primer
Selection. To synthesize a cDNA encoding antibody genes, the restriction sites used for cloning the antibody genes cannot also be present in the variable region DNA sequences to be cloned. Therefore, a computer search of Kabat's nucleotide data base (16) Fig. 1A) .
The sequences of the 5' primers for both VL and VH were based on the N-terminal amino acid sequence of the light and heavy chain of OVB3, respectively (Fig. 1A) . In general, primers were designed so that 23 nucleotides at the 3' end of the primers would not have more than two to five mismatches. These mismatches occur because of variations in the N-terminal and J-region sequences and the degenerate nature of the codons. The base at the 3' end of each primer was either the first or second base of a codon or comple- Fig.  2A) . Also, intact OVB3 competed for the binding (Fig. 2B) . Two of the clones pOVB3 158-1 and pOVB3 158-2 were sequenced (Fig. 3 ). Both the clones had identical coding sequences, indicating that no major changes in sequence were produced in the PCR reaction. However, pOVB3 158-2 did not have an Nde I site; it was missing a C residue of the Nde I restriction site, which did not affect expression of the fusion protein.
These two fusion proteins were minimally toxic to OVCAR3 cells, which was not surprising since chemical conjugates of OVB3 and PE40 have low cytotoxicity toward OVCAR3 cells, and conjugates offull-length PE with OVB3 are very cytotoxic (23) . Therefore, we replaced the PE40 portion of pOVB3158-2 with full-length PE to create pOVB3 154-2 (Fig. 1B) . Upon its expression, protein of the expected size (89 kDa) was produced (Fig. 4, lane A) OVB3 (Fv)-PE bound to OVCAR3 cells (Fig. 2C) , and this could be blocked by competition with excess OVB3, indicating the specificity of the binding (Fig. 2D) .
As shown in Fig. 5 (Table 2 ). The chemical conjugation reaction modifies lysine residues important for the binding of PE to the PE receptor (27) , whereas in the recombinant molecule only the N-terminal amino group is modified. Appropriate mutations in domain I could decrease the nonspecific cytotoxic activity of OVB3 (Fv)-PE.
DISCUSSION
We have described a simple and efficient strategy to clone and express in E. coli genes encoding the VL and VH of mAbs.
The variable-region genes are cloned as a functional singlechain antibody toxin fusion protein whose ability to bind to target cells can be readily assessed either by fluorescence (Fig. 2) or by cytotoxic activity (Fig. 4) . The strategy takes advantage of the fact that the 5' ends of the genes encoding mature VL and VH are very much conserved; similarly, at the 3' end the J-region sequences are also conserved. Primers based on these sequences can be designed for PCR to amplify VL and VH sequences starting from RNA, and restriction sites can be created for cloning (12) . Computer analysis of published VL and VH sequences shows that there are many different restriction sites that are rarely present in antibody genes and would be useful for cloning these fragments (Table  1) . We selected Nde I and HindIII sites for cloning because these are present in our toxin expression vector, but based on Table 1 it should be possible to engineer other cloning sites not found in antibodies to clone fragments into either prokaryotic or eukaryotic expression vectors to make chimeric antibodies. In the case of OVB3, the N-terminal amino acid sequences of the variable regions were available and the primers were based on these sequences. However, if protein sequence data were not available, it is possible to use primers with degenerate codons to clone variable-region genes (12, 14) . Some of the sites used previously (12) for cloning VL and VH genes may not be generally useful because of the high probability of the sites being present in the VL or VH regions of many antibodies (Table 1) . 10 20 Previous strategies for cloning variable-region genes of antibodies from RNA have had to reassemble the individual genes into a functional antibody by subcloning and expression in mammalian vectors (12) . This approach is slow and tedious and requires several subcloning steps and the growth of antibody-producing cells in tissue culture. Using the method described here, from total RNA it is possible to isolate functional antibody genes in 1-2 weeks. Because the chimeric antibody-toxin molecule is made in E. coli, it is possible to make large amounts of the reagent for various types of biochemical and biological studies (8) .
The choice of the linker used to make the single-chain immunotoxin may be very important. We have previously reported a very active immunotoxin, anti-Tac (Fv)-PE40, that contained a linker composed of glycine and serine residues (8) . The linker used in the current construction contains several charged amino acids (Fig. 1B) , some of which were introduced for convenience of cloning.
It has been previously pointed out that it should be possible to directly clone functional antibody genes from the spleens of immunized mice or from B cells of humans by using appropriate primers and PCR-based gene amplification (12, 14) . The ability to clone such sequences as functional singlechain antibodies whose activity can be readily detected by fluorescence or in cytotoxic assays should make this goal more readily achievable.
